JP2017503842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503842A5 JP2017503842A5 JP2016548172A JP2016548172A JP2017503842A5 JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5 JP 2016548172 A JP2016548172 A JP 2016548172A JP 2016548172 A JP2016548172 A JP 2016548172A JP 2017503842 A5 JP2017503842 A5 JP 2017503842A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cell lymphoma
- therapeutic agent
- hodgkin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931075P | 2014-01-24 | 2014-01-24 | |
| US201461931078P | 2014-01-24 | 2014-01-24 | |
| US61/931,078 | 2014-01-24 | ||
| US61/931,075 | 2014-01-24 | ||
| US201462077127P | 2014-11-07 | 2014-11-07 | |
| US62/077,127 | 2014-11-07 | ||
| PCT/US2015/012733 WO2015112888A1 (en) | 2014-01-24 | 2015-01-23 | Apilimod compositions and methods for using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201440A Division JP2021046430A (ja) | 2014-01-24 | 2020-12-04 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503842A JP2017503842A (ja) | 2017-02-02 |
| JP2017503842A5 true JP2017503842A5 (cg-RX-API-DMAC10.html) | 2018-03-08 |
| JP6855243B2 JP6855243B2 (ja) | 2021-04-07 |
Family
ID=53681989
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548172A Expired - Fee Related JP6855243B2 (ja) | 2014-01-24 | 2015-01-23 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| JP2020201440A Pending JP2021046430A (ja) | 2014-01-24 | 2020-12-04 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201440A Pending JP2021046430A (ja) | 2014-01-24 | 2020-12-04 | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10179135B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3096757B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP6855243B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102320190B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN106659716B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2015209133B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112016017112A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2937655C (cg-RX-API-DMAC10.html) |
| IL (1) | IL246879B (cg-RX-API-DMAC10.html) |
| MX (1) | MX373818B (cg-RX-API-DMAC10.html) |
| RU (2) | RU2016134406A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015112888A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015209133B2 (en) | 2014-01-24 | 2019-10-03 | AI Therapeutics, Inc. | Apilimod compositions and methods for using same |
| CN107249638B (zh) | 2014-11-07 | 2021-05-14 | 人工智能治疗公司 | 阿匹莫德用于治疗肾癌 |
| ES2734081T3 (es) * | 2014-11-07 | 2019-12-04 | Ai Therapeutics Inc | Apilimod para el uso en el tratamiento de melanoma |
| WO2016118709A1 (en) * | 2015-01-23 | 2016-07-28 | Lam Therapeutics, Inc. | Anti-viral compositions containing pikfyve inhibitors and use thereof |
| US20180078561A1 (en) * | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| JP2019502707A (ja) * | 2016-01-21 | 2019-01-31 | ラム・セラピューティクス，インコーポレーテッド | 癌をアピリモドで処置するためのバイオマーカー |
| KR20180015441A (ko) | 2016-08-03 | 2018-02-13 | 엘지전자 주식회사 | 롤리 키보드 |
| MX2019002185A (es) * | 2016-08-25 | 2019-09-19 | Ai Therapeutics Inc | Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos. |
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| US10751345B2 (en) | 2018-02-21 | 2020-08-25 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| CN110496128B (zh) * | 2019-09-23 | 2022-09-30 | 吉林大学 | 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用 |
| US12486274B2 (en) | 2020-01-13 | 2025-12-02 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| BR112023025552A2 (pt) * | 2021-06-11 | 2024-02-27 | Orphai Therapeutics Inc | Composições estabilizadas de apilimod e usos das mesmas |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| EP0728218B1 (en) | 1993-11-12 | 2008-01-02 | PHRI Properties, Inc. | Hybridization probes for nucleic acid detection, universal stems, methods and kits |
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| WO2005076843A2 (en) | 2004-02-06 | 2005-08-25 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating tumors and metastatic disease |
| TWI380816B (zh) * | 2004-04-13 | 2013-01-01 | Synta Pharmaceuticals Corp | 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑 |
| JP2008512490A (ja) | 2004-09-08 | 2008-04-24 | チェルシー・セラピューティクス，インコーポレイテッド | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
| TW200630363A (en) | 2004-11-10 | 2006-09-01 | Synta Pharmaceuticals Corp | Process for preparing trisubstituted pyrimidine compounds |
| TW200720256A (en) | 2005-05-13 | 2007-06-01 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| CA2630271C (en) | 2005-11-17 | 2014-04-08 | Osi Pharmaceuticals, Inc. | Fused bicyclic mtor inhibitors |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| EP1981890A2 (en) | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
| ES2780193T3 (es) | 2006-07-12 | 2020-08-24 | Univ Tennessee Res Found | Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina |
| CA2675558A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP5258331B2 (ja) * | 2008-03-03 | 2013-08-07 | ロート製薬株式会社 | 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物 |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| EP3023426A1 (en) | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| EP3338770B1 (en) * | 2010-03-08 | 2023-06-07 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
| JP5783499B2 (ja) | 2010-03-29 | 2015-09-24 | 味の素株式会社 | フェニルアラニン誘導体を含有する医薬製剤 |
| US8402515B2 (en) | 2010-05-06 | 2013-03-19 | Jonathan Weizman | Apparatus and method for establishing a peer-to-peer communication session with a client device |
| US20110287018A1 (en) | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of Treating Interstitial Cystitis |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| GEP201606545B (en) | 2010-11-19 | 2016-09-26 | Ecole Polytech | 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| HK1214128A1 (zh) | 2012-10-05 | 2016-07-22 | Bluelink Pharmaceuticals, Inc. | 癌症的治療 |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| AU2015209133B2 (en) | 2014-01-24 | 2019-10-03 | AI Therapeutics, Inc. | Apilimod compositions and methods for using same |
| ES2734081T3 (es) | 2014-11-07 | 2019-12-04 | Ai Therapeutics Inc | Apilimod para el uso en el tratamiento de melanoma |
| CN107249638B (zh) | 2014-11-07 | 2021-05-14 | 人工智能治疗公司 | 阿匹莫德用于治疗肾癌 |
| WO2016126707A1 (en) | 2015-02-03 | 2016-08-11 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| US20180078561A1 (en) | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| AU2019299234A1 (en) | 2018-07-05 | 2021-01-14 | Mayo Foundation For Medical Education And Research | PIKfyve inhibitors |
| US20210077500A1 (en) | 2019-09-12 | 2021-03-18 | Al Therapeutics, Inc. | Pikfyve inhibitors for cancer therapy |
-
2015
- 2015-01-23 AU AU2015209133A patent/AU2015209133B2/en not_active Ceased
- 2015-01-23 CN CN201580016018.3A patent/CN106659716B/zh not_active Expired - Fee Related
- 2015-01-23 KR KR1020167022474A patent/KR102320190B1/ko not_active Expired - Fee Related
- 2015-01-23 CA CA2937655A patent/CA2937655C/en active Active
- 2015-01-23 BR BR112016017112A patent/BR112016017112A2/pt not_active Application Discontinuation
- 2015-01-23 WO PCT/US2015/012733 patent/WO2015112888A1/en not_active Ceased
- 2015-01-23 RU RU2016134406A patent/RU2016134406A/ru not_active Application Discontinuation
- 2015-01-23 MX MX2016009590A patent/MX373818B/es active IP Right Grant
- 2015-01-23 EP EP15740043.3A patent/EP3096757B1/en active Active
- 2015-01-23 JP JP2016548172A patent/JP6855243B2/ja not_active Expired - Fee Related
- 2015-01-23 RU RU2019107011A patent/RU2019107011A/ru unknown
- 2015-01-23 US US15/113,154 patent/US10179135B2/en active Active
-
2016
- 2016-07-21 IL IL246879A patent/IL246879B/en active IP Right Grant
-
2018
- 2018-11-16 US US16/193,045 patent/US20190183902A1/en not_active Abandoned
-
2019
- 2019-12-27 US US16/728,566 patent/US11266654B2/en not_active Expired - Fee Related
-
2020
- 2020-12-04 JP JP2020201440A patent/JP2021046430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| RU2019107011A (ru) | Композиции апилимода и способы их применения | |
| EP2562177A3 (en) | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof | |
| NZ604040A (en) | The use of inhibitors of bruton’s tyrosine kinase (btk) | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
| JP2016513097A5 (cg-RX-API-DMAC10.html) | ||
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| JP2020505433A5 (cg-RX-API-DMAC10.html) | ||
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| PL2324008T3 (pl) | 3,4-diarylopirazole jako inhibitory kinazy białkowej | |
| WO2006035434A3 (en) | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases | |
| EA201201403A1 (ru) | Очень низкодозированные твердые пероральные лекарственные формы для гзт | |
| EP4269439A3 (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| SG10201901677YA (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| JP2016539156A5 (cg-RX-API-DMAC10.html) | ||
| JP2018090566A5 (cg-RX-API-DMAC10.html) | ||
| MX2007006066A (es) | Inhibidores de jnk para el tratamiento de lesiones del snc. | |
| JP2016529285A5 (cg-RX-API-DMAC10.html) | ||
| MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| JP2016515586A5 (cg-RX-API-DMAC10.html) | ||
| JP2018503610A5 (cg-RX-API-DMAC10.html) |